- 1 Information about Dulaglutide
- 2 Liver safety of Dulaglutide
- 3 Mechanism of action of Dulaglutide
- 4 FDA approval information for Dulaglutide
- 5 Brand name for Dulaglutide
- 6 Dosage and administration for Dulaglutide
- 7 Side effects of Dulaglutide
- 8 Articles on Dulaglutide
- 9 Learn more about Dulaglutide
Information about Dulaglutide
Dulaglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
Liver safety of Dulaglutide
There have been no published reports of hepatotoxicity attributed to dulaglutide therapy.
Mechanism of action of Dulaglutide
Dulaglutide (doo" la gloo' tide) is a glucagon-like peptide-1 (GLP-1) analogue that acts like the native gastrointestinal hormone (incretin) to increase insulin secretion. Dulaglutide reproduces the activity of GLP-1, binding to specific receptors on pancreatic beta cells and increasing insulin secretion, which can lead to improvement of glycemic control in patients with type 2 diabetes. Dulaglutide, like other GLP-1 analogues, also causes weight loss which may contribute to its clinical effects. Dulaglutide is a recombinant DNA produced polypeptide that shares 97% homology to endogenous human GLP-1(7-37), but has an amino acid substitution which makes it resistant to DPP-4 degradation and thus extends its half-life in serum. In addition, the GLP-1 like polypeptide is linked to an Fc fragment of human IgG4 which further prolongs its serum half-life and duration of activity. Dulaglutide, like other GLP-1 analogues, must be given parenterally.
FDA approval information for Dulaglutide
Dulaglutide was approved for use in the United States in 2014 and current indications are for management of glycemic control in adults with type 2 diabetes in combination with diet and exercise, with or without other oral hypoglycemic agents.
Brand name for Dulaglutide
Dulaglutide is available under the brand name Trulicity in solution for subcutaneous injection in prefilled, single dose pens or syringes (0.75 and 1.5 mg/0.5 mL).
Dosage and administration for Dulaglutide
The typical initial dose is 0.75 mg once weekly, which can be increased to 1.5 mg weekly.
Side effects of Dulaglutide
Dulaglutide is generally well tolerated, but side effects can be dose limiting and include nausea [~20%], vomiting [~5%], diarrhea [~12%], abdominal pain, decreased appetite,dyspepsia and fatigue. Rare side effects include pancreatitis [0.1-0.3%], hypoglycemia and hypersensitivity reactions.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors